Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Hydrogel microspheres evading alveolar macrophages for sustained pulmonary protein delivery.

Graf M, Ziegler CE, Gregoritza M, Goepferich AM.

Int J Pharm. 2019 Jul 20;566:652-661. doi: 10.1016/j.ijpharm.2019.06.019. Epub 2019 Jun 8.

PMID:
31181308
2.

Influenza A virus mimetic nanoparticles trigger selective cell uptake.

Maslanka Figueroa S, Veser A, Abstiens K, Fleischmann D, Beck S, Goepferich A.

Proc Natl Acad Sci U S A. 2019 May 14;116(20):9831-9836. doi: 10.1073/pnas.1902563116. Epub 2019 Apr 29.

PMID:
31036631
3.

Intracellular availability of poorly soluble drugs from lipid nanocapsules.

Bohley M, Haunberger A, Goepferich AM.

Eur J Pharm Biopharm. 2019 Jun;139:23-32. doi: 10.1016/j.ejpb.2019.03.007. Epub 2019 Mar 7.

PMID:
30851353
4.

Interaction of functionalized nanoparticles with serum proteins and its impact on colloidal stability and cargo leaching.

Abstiens K, Maslanka Figueroa S, Gregoritza M, Goepferich AM.

Soft Matter. 2019 Jan 28;15(4):709-720. doi: 10.1039/c8sm02189a. Epub 2019 Jan 9.

PMID:
30624437
5.

Ligand Density and Linker Length are Critical Factors for Multivalent Nanoparticle-Receptor Interactions.

Abstiens K, Gregoritza M, Goepferich AM.

ACS Appl Mater Interfaces. 2019 Jan 9;11(1):1311-1320. doi: 10.1021/acsami.8b18843. Epub 2018 Dec 20.

PMID:
30521749
6.

Nanoparticles Targeting Retinal and Choroidal Capillaries In Vivo.

Haunberger A, Goepferich A.

Methods Mol Biol. 2019;1834:391-404. doi: 10.1007/978-1-4939-8669-9_25.

PMID:
30324457
7.

Fabrication of antibody-loaded microgels using microfluidics and thiol-ene photoclick chemistry.

Gregoritza M, Abstiens K, Graf M, Goepferich AM.

Eur J Pharm Biopharm. 2018 Jun;127:194-203. doi: 10.1016/j.ejpb.2018.02.024. Epub 2018 Feb 19.

PMID:
29471077
8.

Alkaline poly(ethylene glycol)-based hydrogels for a potential use as bioactive wound dressings.

Koehler J, Verheyen L, Hedtrich S, Brandl FP, Goepferich AM.

J Biomed Mater Res A. 2017 Dec;105(12):3360-3368. doi: 10.1002/jbm.a.36177. Epub 2017 Sep 20.

PMID:
28782253
9.

Controlled Antibody Release from Degradable Thermoresponsive Hydrogels Cross-Linked by Diels-Alder Chemistry.

Gregoritza M, Messmann V, Abstiens K, Brandl FP, Goepferich AM.

Biomacromolecules. 2017 Aug 14;18(8):2410-2418. doi: 10.1021/acs.biomac.7b00587. Epub 2017 Jul 6.

PMID:
28639788
10.

Targeting the Central Nervous System (CNS): A Review of Rabies Virus-Targeting Strategies.

Oswald M, Geissler S, Goepferich A.

Mol Pharm. 2017 Jul 3;14(7):2177-2196. doi: 10.1021/acs.molpharmaceut.7b00158. Epub 2017 Jun 16. Review.

PMID:
28514853
11.

Polyanion based controlled release system for the GnRH-receptor antagonist degarelix.

Backofen M, Schwach G, Koechling W, Weiss T, Goepferich A.

Eur J Pharm Sci. 2017 Jun 15;104:65-71. doi: 10.1016/j.ejps.2017.03.036. Epub 2017 Mar 25.

PMID:
28347774
12.

pH-Modulating Poly(ethylene glycol)/Alginate Hydrogel Dressings for the Treatment of Chronic Wounds.

Koehler J, Wallmeyer L, Hedtrich S, Goepferich AM, Brandl FP.

Macromol Biosci. 2017 May;17(5). doi: 10.1002/mabi.201600369. Epub 2016 Dec 20.

PMID:
27995736
13.

Determination of the activity of maleimide-functionalized phospholipids during preparation of liposomes.

Oswald M, Geissler S, Goepferich A.

Int J Pharm. 2016 Nov 30;514(1):93-102. doi: 10.1016/j.ijpharm.2016.06.116.

PMID:
27863688
14.

Polyanions effectively prevent protein conjugation and activity loss during hydrogel cross-linking.

Gregoritza M, Goepferich AM, Brandl FP.

J Control Release. 2016 Sep 28;238:92-102. doi: 10.1016/j.jconrel.2016.07.030. Epub 2016 Jul 21.

PMID:
27448442
15.

Cyclic RGD peptides target human trabecular meshwork cells while ameliorating connective tissue growth factor-induced fibrosis.

Hennig R, Kuespert S, Haunberger A, Goepferich A, Fuchshofer R.

J Drug Target. 2016 Dec;24(10):952-959. doi: 10.3109/1061186X.2016.1163709. Epub 2016 Mar 27.

PMID:
26973018
16.

A life full of life-science polymer research.

Goepferich A, Horstman M.

Eur J Pharm Biopharm. 2015 Nov;97(Pt B):292. doi: 10.1016/j.ejpb.2015.07.006. No abstract available.

PMID:
26614553
17.

HPLC analysis as a tool for assessing targeted liposome composition.

Oswald M, Platscher M, Geissler S, Goepferich A.

Int J Pharm. 2016 Jan 30;497(1-2):293-300. doi: 10.1016/j.ijpharm.2015.11.014. Epub 2015 Nov 10.

PMID:
26570988
18.

Multivalent nanoparticles bind the retinal and choroidal vasculature.

Hennig R, Ohlmann A, Staffel J, Pollinger K, Haunberger A, Breunig M, Schweda F, Tamm ER, Goepferich A.

J Control Release. 2015 Dec 28;220(Pt A):265-274. doi: 10.1016/j.jconrel.2015.10.033. Epub 2015 Oct 19.

PMID:
26494258
19.

Diels-Alder Hydrogels for Controlled Antibody Release: Correlation between Mesh Size and Release Rate.

Kirchhof S, Abrami M, Messmann V, Hammer N, Goepferich AM, Grassi M, Brandl FP.

Mol Pharm. 2015 Sep 8;12(9):3358-68. doi: 10.1021/acs.molpharmaceut.5b00375. Epub 2015 Aug 27.

PMID:
26266700
20.

Diels-Alder hydrogels with enhanced stability: First step toward controlled release of bevacizumab.

Kirchhof S, Gregoritza M, Messmann V, Hammer N, Goepferich AM, Brandl FP.

Eur J Pharm Biopharm. 2015 Oct;96:217-25. doi: 10.1016/j.ejpb.2015.07.024. Epub 2015 Aug 5.

PMID:
26253504
21.

Branched Polymer-Drug Conjugates for Multivalent Blockade of Angiotensin II Receptors.

Hennig R, Veser A, Kirchhof S, Goepferich A.

Mol Pharm. 2015 Sep 8;12(9):3292-302. doi: 10.1021/acs.molpharmaceut.5b00301. Epub 2015 Aug 14.

PMID:
26252154
22.

Hydrogels in ophthalmic applications.

Kirchhof S, Goepferich AM, Brandl FP.

Eur J Pharm Biopharm. 2015 Sep;95(Pt B):227-38. doi: 10.1016/j.ejpb.2015.05.016. Epub 2015 May 29. Review.

PMID:
26032290
23.

Ocular drug delivery.

Goepferich A.

Eur J Pharm Biopharm. 2015 Sep;95(Pt B):157. doi: 10.1016/j.ejpb.2015.05.011. Epub 2015 May 22. No abstract available.

PMID:
26004820
24.

Multivalent targeting of AT1 receptors with angiotensin II-functionalized nanoparticles.

Hennig R, Pollinger K, Tessmar J, Goepferich A.

J Drug Target. 2015;23(7-8):681-9. doi: 10.3109/1061186X.2015.1035276. Epub 2015 May 7.

PMID:
25950599
25.

Oligolayer-coated nanoparticles: impact of surface topography at the nanobio interface.

Wurster EC, Liebl R, Michaelis S, Robelek R, Wastl DS, Giessibl FJ, Goepferich A, Breunig M.

ACS Appl Mater Interfaces. 2015 Apr 22;7(15):7891-900. doi: 10.1021/am508435j. Epub 2015 Apr 7.

PMID:
25815610
26.

Nanoparticles for the treatment of ocular neovascularizations.

Hennig R, Goepferich A.

Eur J Pharm Biopharm. 2015 Sep;95(Pt B):294-306. doi: 10.1016/j.ejpb.2015.02.027. Epub 2015 Mar 7. Review.

PMID:
25758124
27.

Formation of fenestrae in murine liver sinusoids depends on plasmalemma vesicle-associated protein and is required for lipoprotein passage.

Herrnberger L, Hennig R, Kremer W, Hellerbrand C, Goepferich A, Kalbitzer HR, Tamm ER.

PLoS One. 2014 Dec 26;9(12):e115005. doi: 10.1371/journal.pone.0115005. eCollection 2014.

28.

Protein compatibility of selected cross-linking reactions for hydrogels.

Hammer N, Brandl FP, Kirchhof S, Messmann V, Goepferich AM.

Macromol Biosci. 2015 Mar;15(3):405-13. doi: 10.1002/mabi.201400379. Epub 2014 Nov 14.

PMID:
25399803
29.

Nanoparticle multivalency counterbalances the ligand affinity loss upon PEGylation.

Hennig R, Pollinger K, Veser A, Breunig M, Goepferich A.

J Control Release. 2014 Nov 28;194:20-7. doi: 10.1016/j.jconrel.2014.07.062. Epub 2014 Aug 13.

PMID:
25128717
30.

Controlled release of therapeutic antibody formats.

Schweizer D, Serno T, Goepferich A.

Eur J Pharm Biopharm. 2014 Oct;88(2):291-309. doi: 10.1016/j.ejpb.2014.08.001. Epub 2014 Aug 11. Review.

PMID:
25125350
31.

Biodistribution of quantum dots in the kidney after intravenous injection.

Pollinger K, Hennig R, Bauer S, Breunig M, Tessmar J, Buschauer A, Witzgall R, Goepferich A.

J Nanosci Nanotechnol. 2014 May;14(5):3313-9.

PMID:
24734546
32.

Cleavable carbamate linkers for controlled protein delivery from hydrogels.

Hammer N, Brandl FP, Kirchhof S, Goepferich AM.

J Control Release. 2014 Jun 10;183:67-76. doi: 10.1016/j.jconrel.2014.03.031. Epub 2014 Mar 25.

PMID:
24680687
33.

Theme issue: pulmonary delivery of drugs.

Goepferich A.

Eur J Pharm Biopharm. 2014 Jan;86(1):vi. doi: 10.1016/S0939-6411(14)00037-X. No abstract available.

PMID:
24602746
34.

To pause for a moment.

Goepferich A.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):328. doi: 10.1016/j.ejpb.2013.10.010. Epub 2013 Oct 30. No abstract available.

PMID:
24184802
35.

Self-assembling colloidal system for the ocular administration of cyclosporine A.

Luschmann C, Tessmar J, Schoeberl S, Strauß O, Luschmann K, Goepferich A.

Cornea. 2014 Jan;33(1):77-81. doi: 10.1097/ICO.0b013e3182a7f3bf.

PMID:
24162754
36.

Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation.

Schweizer D, Vostiar I, Heier A, Serno T, Schoenhammer K, Jahn M, Jones S, Piequet A, Beerli C, Gram H, Goepferich A.

J Control Release. 2013 Dec 28;172(3):975-82. doi: 10.1016/j.jconrel.2013.10.010. Epub 2013 Oct 15.

PMID:
24140353
37.

Developing an in situ nanosuspension: a novel approach towards the efficient administration of poorly soluble drugs at the anterior eye.

Luschmann C, Tessmar J, Schoeberl S, Strauss O, Framme C, Luschmann K, Goepferich A.

Eur J Pharm Sci. 2013 Nov 20;50(3-4):385-92. doi: 10.1016/j.ejps.2013.07.002. Epub 2013 Jul 20.

PMID:
23880334
38.

Ocular delivery systems for poorly soluble drugs: an in-vivo evaluation.

Luschmann C, Herrmann W, Strauss O, Luschmann K, Goepferich A.

Int J Pharm. 2013 Oct 15;455(1-2):331-7. doi: 10.1016/j.ijpharm.2013.07.002. Epub 2013 Jul 16.

PMID:
23867983
39.

The impact of polyelectrolyte structure on the shape of nanoassemblies with cationic peptides.

Ferstl M, Drechsler M, Rachel R, Rischer M, Engel J, Backofen M, Goepferich A.

J Pharm Sci. 2013 Aug;102(8):2599-607. doi: 10.1002/jps.23619. Epub 2013 May 31.

PMID:
23728779
40.

Ligand-functionalized nanoparticles target endothelial cells in retinal capillaries after systemic application.

Pollinger K, Hennig R, Ohlmann A, Fuchshofer R, Wenzel R, Breunig M, Tessmar J, Tamm ER, Goepferich A.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6115-20. doi: 10.1073/pnas.1220281110. Epub 2013 Mar 25.

41.

RNA "traffic lights": an analytical tool to monitor siRNA integrity.

Holzhauser C, Liebl R, Goepferich A, Wagenknecht HA, Breunig M.

ACS Chem Biol. 2013 May 17;8(5):890-4. doi: 10.1021/cb3006616. Epub 2013 Feb 20.

PMID:
23402653
42.

Premature drug release of polymeric micelles and its effects on tumor targeting.

Miller T, Breyer S, van Colen G, Mier W, Haberkorn U, Geissler S, Voss S, Weigandt M, Goepferich A.

Int J Pharm. 2013 Mar 10;445(1-2):117-24. doi: 10.1016/j.ijpharm.2013.01.059. Epub 2013 Feb 4.

PMID:
23384729
43.

Insulin is essential for in vitro chondrogenesis of mesenchymal progenitor cells and influences chondrogenesis in a dose-dependent manner.

Mueller MB, Blunk T, Appel B, Maschke A, Goepferich A, Zellner J, Englert C, Prantl L, Kujat R, Nerlich M, Angele P.

Int Orthop. 2013 Jan;37(1):153-8. doi: 10.1007/s00264-012-1726-z. Epub 2012 Dec 11.

44.

Drug loading of polymeric micelles.

Miller T, van Colen G, Sander B, Golas MM, Uezguen S, Weigandt M, Goepferich A.

Pharm Res. 2013 Feb;30(2):584-95. doi: 10.1007/s11095-012-0903-5. Epub 2012 Nov 8.

PMID:
23135819
45.

Layer-by-layer coated gold nanoparticles: size-dependent delivery of DNA into cells.

Elbakry A, Wurster EC, Zaky A, Liebl R, Schindler E, Bauer-Kreisel P, Blunk T, Rachel R, Goepferich A, Breunig M.

Small. 2012 Dec 21;8(24):3847-56. doi: 10.1002/smll.201201112. Epub 2012 Aug 22.

PMID:
22911477
46.

Kidney podocytes as specific targets for cyclo(RGDfC)-modified nanoparticles.

Pollinger K, Hennig R, Breunig M, Tessmar J, Ohlmann A, Tamm ER, Witzgall R, Goepferich A.

Small. 2012 Nov 5;8(21):3368-75. doi: 10.1002/smll.201200733. Epub 2012 Aug 8.

PMID:
22888052
47.

A library of strictly linear poly(ethylene glycol)-poly(ethylene imine) diblock copolymers to perform structure-function relationship of non-viral gene carriers.

Bauhuber S, Liebl R, Tomasetti L, Rachel R, Goepferich A, Breunig M.

J Control Release. 2012 Sep 10;162(2):446-55. doi: 10.1016/j.jconrel.2012.07.017. Epub 2012 Jul 20.

PMID:
22820448
48.

Targeting drugs to mitochondria.

Heller A, Brockhoff G, Goepferich A.

Eur J Pharm Biopharm. 2012 Sep;82(1):1-18. doi: 10.1016/j.ejpb.2012.05.014. Epub 2012 Jun 9. Review.

PMID:
22687572
49.

Long time monitoring of the respiratory activity of isolated mitochondria.

Heller A, Fischer LH, Wolfbeis OS, Goepferich A.

Exp Cell Res. 2012 Aug 15;318(14):1667-72. doi: 10.1016/j.yexcr.2012.05.007. Epub 2012 May 30.

PMID:
22659171
50.

Analysis of immediate stress mechanisms upon injection of polymeric micelles and related colloidal drug carriers: implications on drug targeting.

Miller T, Hill A, Uezguen S, Weigandt M, Goepferich A.

Biomacromolecules. 2012 Jun 11;13(6):1707-18. doi: 10.1021/bm3002045. Epub 2012 May 16. Review.

PMID:
22462502

Supplemental Content

Loading ...
Support Center